Intellectual Capital in Public-Private Partnerships in Health Care: the EMIF Project of the Innovative Medicines Initiative PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Intellectual Capital in Public-Private Partnerships in Health Care: the EMIF Project of the Innovative Medicines Initiative PDF full book. Access full book title Intellectual Capital in Public-Private Partnerships in Health Care: the EMIF Project of the Innovative Medicines Initiative by Linne Van den Brande. Download full books in PDF and EPUB format.
Author: Linne Van den Brande
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Linne Van den Brande
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author:
Publisher:
ISBN: 9789295207103
Category :
Languages : en
Pages : 13
Get Book Here
Book Description
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
The Innovative Medicines Initiative (IMI) is a partnership between the European Union, represented by the European Commission, and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas of unmet medical or social need. IMI does this by facilitating collaboration between the key players in health research, including universities, pharmaceutical companies, small and medium-sized enterprises (SMEs), patient organisations, and others. IMI has a total budget of over €5 billion for the period 2008-2024. Half of this comes from the EU's research and innovation programmes, while the other half comes from EFPIA members as well as some other large organisations and companies.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309301718
Category : Medical
Languages : en
Pages : 88
Get Book Here
Book Description
Scientific advances such as the sequencing of the human genome have created great promise for improving human health by providing a greater understanding of disease biology and enabling the development of new drugs, diagnostics, and preventive services. However, the translation of research advances into clinical applications has so far been slower than anticipated. This is due in part to the complexity of the underlying biology as well as the cost and time it takes to develop a product. Pharmaceutical companies are adapting their business models to this new reality for product development by placing increasing emphasis on leveraging alliances, joint development efforts, early-phase research partnerships, and public-private partnerships. These collaborative efforts make it possible to identify new drug targets, enhance the understanding of the underlying basis of disease, discover novel indications for the use of already approved products, and develop biomarkers for disease outcomes or directed drug use. While the potential benefits of collaboration are significant, the fact that the relationships among development partners are often financial means that it is vital to ensure trust by identifying, disclosing, and managing any potential sources of conflict that could create bias in the research being performed together. Conflict of Interest and Medical Innovation is the summary of a workshop convened by the Institute of Medicine Roundtable on Translating Genomic-Based Research for Health in June 2013 to explore the appropriate balance between identifying and managing conflicts of interest and advancing medical innovation. A wide range of stakeholders, including government officials, pharmaceutical company representatives, academic administrators and researchers, health care providers, medical ethicists, patient advocates, and consumers, were invited to present their perspectives and participate in discussions during the workshop. This report focuses on current conflict of interest policies and their effect on medical innovation in an effort to identify best practices and potential solutions for facilitating innovation while still ensuring scientific integrity and public trust.
Author:
Publisher:
ISBN: 9789295207134
Category :
Languages : en
Pages :
Get Book Here
Book Description
The innovative medicines initiative (IMI) was launched in 2008 as a public-private partnership between the European Union and the European Federation of Pharmaceutical industries and Associations (EFPIA). We are working to improve health by speeding up the development of innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by covering the full spectrum of drug discovery and development, from understanding the underlying causes of disease and identifying potential drugs and drug targets, through testing potential drugs for safety and efficacy, to clinical trial design, and monitoring the benefits and risks of medicines and vaccines once they are in use. In our second phase, IMI2, we remain focused on the needs of patients and society, and on delivering tools and resources to speed up the development of urgently-needed treatments. In line with Horizon 2020, we also cover the later stages of drug development, and are working more closely with partners from other sectors (e.g. diagnostics, animal health, IT, imaging, etc.).
Author: Hannah E. Kettler
Publisher:
ISBN: 9781899040520
Category : Public-private sector cooperation
Languages : en
Pages : 135
Get Book Here
Book Description
Author: Anton Bespalov
Publisher: Springer Nature
ISBN: 3030336565
Category : Cardiology
Languages : en
Pages : 424
Get Book Here
Book Description
This open access book, published under a CC BY 4.0 license in the Pubmed indexed book series Handbook of Experimental Pharmacology, provides up-to-date information on best practice to improve experimental design and quality of research in non-clinical pharmacology and biomedicine.
Author: Congressional Budget Office
Publisher: Lulu.com
ISBN: 1304121445
Category : Science
Languages : en
Pages : 65
Get Book Here
Book Description
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author: Karolina Krysinska
Publisher:
ISBN: 9780733437557
Category : Dementia
Languages : en
Pages : 158
Get Book Here
Book Description
"Patient registries are well embedded in many fields of medicine and public health, including cancer and cardiovascular diseases. Still, registries collecting data on patients with dementia are relatively new. Also, despite many advantages and tangible practical outcomes, to-date only a limited number of organisations systematically collect dementia data on a national or local/regional level. This report presents the current situation in regards to dementia registries worldwide. The document is based on a systematic review of dementia registries and a review of the literature on best practice in establishing and operating patient and health services/quality registries."--Page 9.
Author: Indian Agricultural Research Institute
Publisher:
ISBN:
Category : Agriculture
Languages : en
Pages : 698
Get Book Here
Book Description
